Kerkhof Marjan, Tran Trung N, Allehebi Riyad, Canonica G Walter, Heaney Liam G, Hew Mark, Perez de Llano Luis, Wechsler Michael E, Bulathsinhala Lakmini, Carter Victoria A, Chaudhry Isha, Eleangovan Neva, Murray Ruth B, Price Chris A, Price David B
Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.
AstraZeneca, Gaithersburg, Md.
J Allergy Clin Immunol Pract. 2021 Dec;9(12):4353-4370. doi: 10.1016/j.jaip.2021.07.056. Epub 2021 Aug 14.
We developed an eosinophil phenotype gradient algorithm and applied it to a large severe asthma cohort (International Severe Asthma Registry).
We sought to reapply this algorithm in a UK primary care asthma cohort, quantify the eosinophilic phenotype, and assess the relationship between the likelihood of an eosinophilic phenotype and asthma severity/health care resource use (HCRU).
Patients age 13 years and older with active asthma and blood eosinophil count or 1 or greater, who were included from the Optimum Patient Care Research Database and the Clinical Practice Research Datalink, were categorized according to the likelihood of eosinophilic phenotype using the International Severe Asthma Registry gradient eosinophilic algorithm. Patient demographic, clinical and HCRU characteristics were described for each phenotype.
Of 241,006 patients, 50.3%, 22.2%, and 21.9% most likely (grade 3), likely (grade 2), and least likely (grade 1), respectively, had an eosinophilic phenotype, and 5.6% had a noneosinophilic phenotype (grade 0). Compared with patients with noneosinophilic asthma, those most likely to have an eosinophilic phenotype tended to have more comorbidities (percentage with Charlson comorbidity index of ≥2: 28.2% vs 6.9%) and experienced more asthma attacks (percentage with one or more attack: 24.8% vs 15.3%). These patients were also more likely to have asthma that was difficult to treat (31.1% vs 18.3%), to receive more intensive treatment (percentage on Global Initiative for Asthma 2020 step 4 or 5: 44.2% vs 27.5%), and greater HCRU (eg, 10.8 vs 7.9 general practitioner all-cause consultations per year).
The eosinophilic asthma phenotype predominates in primary care and is associated with greater asthma severity and HCRU. These patients may benefit from earlier and targeted asthma therapy.
我们开发了一种嗜酸性粒细胞表型梯度算法,并将其应用于一个大型重度哮喘队列(国际重度哮喘注册研究)。
我们试图在英国基层医疗哮喘队列中重新应用该算法,量化嗜酸性粒细胞表型,并评估嗜酸性粒细胞表型可能性与哮喘严重程度/医疗保健资源利用(HCRU)之间的关系。
从最佳患者护理研究数据库和临床实践研究数据链中纳入年龄在13岁及以上、患有活动性哮喘且血液嗜酸性粒细胞计数为1或更高的患者,使用国际重度哮喘注册研究梯度嗜酸性粒细胞算法根据嗜酸性粒细胞表型可能性进行分类。描述了每种表型患者的人口统计学、临床和HCRU特征。
在241,006名患者中,分别有50.3%、22.2%和21.9%最有可能(3级)、有可能(2级)和最不可能(1级)具有嗜酸性粒细胞表型,5.6%具有非嗜酸性粒细胞表型(0级)。与非嗜酸性粒细胞性哮喘患者相比,最有可能具有嗜酸性粒细胞表型的患者往往合并症更多(Charlson合并症指数≥2的百分比:28.2%对6.9%),哮喘发作次数更多(有一次或多次发作的百分比:24.8%对15.3%)。这些患者也更有可能患有难治性哮喘(31.1%对18.3%),接受更强化的治疗(2020年全球哮喘防治创议第4或5步的百分比:44.2%对27.5%),以及更高的HCRU(例如,每年全科医生全因会诊次数为10.8次对7.9次)。
嗜酸性粒细胞性哮喘表型在基层医疗中占主导地位,且与更高的哮喘严重程度和HCRU相关。这些患者可能从早期和有针对性的哮喘治疗中获益。